ACRP CCRC EXAM PREP QUESTIONS LATEST
2023/2024 GRADED A+
What are expected or possible consequences of over-estimation of recruitment
potential? - - The trial will overrun its projected timeline
- The recruitment period will be prolonged and more sites may be needed - The study
will not have sufficient data within the required timeframe and will be stopped because
of lack of budget
What should be the first consideration when conducting a clinical trial? - Subject welfare
When is the investigator allowed to deviate from the protocol? - When there is an
immediate hazard to a patient.
If the investigator wanted to deviate from the protocol for an immediate hazard to a
patient, according to ICH E6 guidelines who world they need to report the deviation and
rationale to, if appropriate? - - The Sponsor
- IRB/IEC
- Regulatory Authorities
Which conditions should be fulfilled when enrolling a subject into your trial? - - Subject
meets all inclusion criteria
- Subject has given written informed consent
You've been delegated to handle the storage and inventory of IP. The study drug must
be stored below 25C/77F. On a summer Monday morning you discover that the
temperature recording machine in the storage room has failed so you doin't know what
the temperature has been over the weekend. You check the current temperature; it's
24C/75F. What should you do? - - Contact the Sponsor, explain what happened and
ask for instructions
- Set up a site staff meeting to conduct a root cause analysis
A protocol amendment was issued for a trial. Your site received IRB approval for the
amendment and wants to implement the increase in PO dose for your trial subjects as
identified in the amendment trial subjects. As delegated consenting duties you must
reconsent trial subjects before being able to administer the adjusted dose. You decide to
only re-consent trial subjects who are still taking the IP and not from the subjects woh
,already completed their drug intake period. Is this allowed according the E6 Guideline
for GCP? - No, these subjects are still enrolled in the trial and therefore need to be
updated on any changes to the protocol.
A trial subject informs you she no longer wants to participant in the trial. What should
your course of action be? - You ask if the patient wishes to share the reason why she
wants to leave the trial. If not, you exclude the subject from the trial immediately.
A patient cannot recall the name of the heart condition medication he took a few years
ago. This is important information for deciding whether the patient may be enrolled in a
clinical trial (IC/EC). What's your best course of action? - You attempt to retrieve the
patients medical history by contacting previous caregivers and you wait for additional
information before enrollment.
Who has ultimate trial responsibility for each subject? - The principle investigator.
A trial subject suffers from severe repeat headaches. Should this adverse event be
reported to the IRB? - No
What statements are true concerning an adverse drug reaction? - - All noxious and
unintended responses to a medicinal product related to any dose should be considered
as an ADR
- An ADR suggests a relationship to trail medication
- All ADRs must be documented
What Adverse Events (AEs) are Serious Adverse Events (SAEs)? - - Any AE that
results in death
- Any AE that results in inpatient hospitalization
- Any AE that is a congenital anomaly
During a study visit a patient tells the investigator that she visited an emergency room
and received intensive treatment for allergic bronchospasm. Since the patient was in the
emergency room for only three hours, the investigator did not assess the event as
serious. Is this a correct assessment? - No, this would be a medically important event
and should be considered serious
What data points minimally need to be reported by the site when reporting an SAE, so
that the sponsor can process the event? - Identification of event, product, and trial
subject
During a visit with investigator, a subject reported feeling heart palpitations for a brief
period of time during the previous evening. The heart palpitations resolved without
reoccurrence. The investigator considered these symptoms to be unrelated to study
, drug. The next day, the subject told a fellow student that he felt tired and was planning
on taking a nap. Later, the subject was found dead. A preliminary report from the
medical examiner indicated the subject died of pulmonary embolism. What should your
next course of action be? - - Record these events in case report form
- Immediately notify sponsor about serious adverse events
When asked by a regulatory body why they received SAE related information on
12/2013 from an incident that occurred in 5/2013, the sponsor explained the reason
being they received the trial related SAE information from the investigator in 12/2013. Is
the sponsor correct in only holding the investigator accountable for their late reporting? -
No, the sponsor should support the conduct QC activities with the sites to help them
ensure timely SAE reporting.
A trial subject in a cardiology trial is admitted to hospital with heart attack. The
investigator considers this event possibly related to the study drug even though this is
not listed in the IB as a potential adverse reaction. What would the investigator report
this event to the sponsor as? - An unexpected, serious adverse event
A 22y/o male was entered into a clinical study for treatment of schizophrenia The study
drug was administered orally, BID. One week later, the subject visited the investigator
complaining of sever sore throat. The IB lists this as an occurrence reported by 1% of
subjects receiving drug. How should this severe throat be classified? - - An adverse
event
- An adverse drug reaction
In regards to AE and ADR reporting, what statements are true? - - All ADRs are AEs but
not all AEs are ADRs
- Worsening in pre-existing medical conditions is an AE
-Preplanned hospitalization is usually not an SAE
What determines the causality of an adverse event? - The investigator
Which term best describes the cyclical process that involves the Plan, Do, Check, Act
activities? - Quality improvement
Which term best describes an independent assessment of completed work to ensure it
will meet applicable quality standards? - Quality assurance
Which term best describes the activities done to ensure quality output? - Quality control
Which term requires structure and a definition of acceptable standards of performance?
- Quality planning
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller brendawambui0309. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $16.49. You're not tied to anything after your purchase.
